Antibiotics

A team of researchers at Stevens Institute of Technology are working on the development of a rapid, cost-effective diagnostic test for the detection of bacterial and viral infections.

Jason Pogue, PharmD, BCPS-ID, explains how ceftolozane-tazobactam differs from other beta-lactams for treating Pseudomonas infections.

Milena McLaughlin, PharmD, MSc, explains ways to remain vigilant when it comes to drug shortages.

Elizabeth Phillips, MD, FRCPC, FRACP, addresses the misconceptions about penicillin allergies.

The Centers for Disease Control and Prevention (CDC) is providing local agencies with a boost—in the form of $200 million—to improve surveillance, laboratory diagnostic capabilities, and outbreak response.

Jason Pogue, PharmD, BCPS-ID, explains his team’s study regarding the susceptibility of Pseudomonas isolates to ceftolozane/tazobactam.

Milena McLaughlin, PharmD, MSc, explains the best way to determine an alternative agent during a drug shortage.

Jason Gallagher, PharmD, BCPS, FCCP, FIDSA, explains how restrictions on commercial automated susceptibility testing can affect patient care.

A research team from the Netherlands turns to deep sequencing technology to detect hepatitis C virus resistant variants.

Arjun Srinivasan, MD, shares how to focus your efforts for infectious disease outbreak investigations.

New research suggests that a vaccine designed to protect against meningitis may also protect against gonorrhea infections.

Meghan Jeffres, PharmD, explains the importance of discussing cross-reactivity among beta-lactams.

For the most challenging of microbial threats, one microbiologist is trying an old tactic in a new era.

Cases of antibiotic-resistant gonorrhea are on the rise, and the bacteria may soon become untreatable if new antibiotics and diagnostic tools are not developed.

Milena McLaughlin, PharmD, MSc, explains different strategies institutions can take to obtain antimicrobials that are on shortage.

Penn researchers find that cases of recurrent C. difficile infections are rapidly increasing, underscoring the need for new treatment options, such as fecal microbiota transplants.

Jason Pogue, PharmD, BCPS-ID, explains the limitations of the current drugs for the treatment of Pseudomonas aeruginosa infections.